Biocompatibles UK, a medical technology company involved in drug device combination products, has won an award for the development of an innovative cancer product.
The Farnham, Surrey based firm received the Institute of Materials, Minerals and Mining (IOM3) award for Polymers in the Service of Mankind for its DC Bead technology from HRH The Prince Philip, in a ceremony at Buckingham Palace.
DC Bead is a polymer-based engineering solution that ultimately deprives cancer of the nutrients and oxygen that enable it to spread. It is used in a procedure called Transarterial Chemoembolisation (TACE), a minimally invasive medical procedure to restrict a tumour's blood supply. TACE has been used extensively to delay the progression of hepatocellular carcinoma (HCC), a type of liver cancer.
Biocompatibles UK’s main aim is to deliver products that are safe to use, economically viable, with clear clinical advantages. The firm's products use specialised polymer technology engineered to allow ease of delivery to blood vessels of tumours combined with controlled drug delivery capability. It is a pioneer in the use of drug-eluting beads to treat cancer.
Biocompatibles UK Ltd has been part of BTG International group company since 2008.
The Prince Philip award was established in 1973 and is awarded biennually (subject to sufficient merit).
Biocompatibles wins IOM3 award for DC Bead technology
Polymer-based engineering solution deprives cancer cells of nutrients they need to survive
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Sustainability
Redefining safety, efficiency, and sustainability: SCHOTT Pharma launches next generation polymer syringe system
A new cap design for prefillable polymer syringes provides tamper evidence at the individual syringe level, significantly reducing the risk of drug waste and ensuring patient safety. The integrated label concept, developed with Schreiner MediPharm, offers reliable first-opening indication, oxygen and light protection, and can include an RFID chip for accurate drug traceability and inventory management. A carton secondary packaging eliminates the need for blister packs, reducing waste and saving valuable storage space in hospitals and during transport, thereby cutting the carbon footprint of the entire value chain by up to 58%
Pharmaceutical
CellCarta and Leica Biosystems expand companion disgnostic development model partnership
Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation